Neisseria meningitidis serogroup W, Burkina Faso, 2012

49Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsATT). During 2012, Burkina Faso reported increases in Neisseria meningitidis serogroup W, raising questions about whether these cases were a natural increase in disease or resulted from serogroup replacement after PsA-TT introduction. We analyzed national surveillance data to describe the epidemiology of serogroup W and genotyped 61 serogroup W isolates. In 2012, a total of 5,807 meningitis cases were reported through enhanced surveillance, of which 2,353 (41%) were laboratory confirmed. The predominant organism identified was N. meningitidis serogroup W (62%), and all serogroup W isolates characterized belonged to clonal complex 11. Although additional years of data are needed before we can understand the epidemiology of serogroup W after PsA-TT introduction, these data suggest that serogroup W will remain a major cause of sporadic disease and has epidemic potential, underscoring the need to maintain high-quality case-based meningitis surveillance after PsA-TT introduction.

Cite

CITATION STYLE

APA

MacNeil, J. R., Medah, I., Koussoubé, D., Novak, R. T., Cohn, A. C., Diomandé, F. V. K., … Messonnier, N. E. (2014). Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerging Infectious Diseases, 20(3), 394–399. https://doi.org/10.3201/eid2003.131407

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free